India · Delayed Price · Currency is INR Orchid Pharma Statistics
Total Valuation
Orchid Pharma has a market cap or net worth of INR 50.87 billion. The enterprise value is 53.67 billion.
| Market Cap | 50.87B |
| Enterprise Value | 53.67B |
Important Dates
The last earnings date was Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Orchid Pharma has 50.72 million shares outstanding. The number of shares has decreased by -0.08% in one year.
| Current Share Class | 50.72M |
| Shares Outstanding | 50.72M |
| Shares Change (YoY) | -0.08% |
| Shares Change (QoQ) | -0.40% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 24.43% |
| Float | 50.72M |
Valuation Ratios
The trailing PE ratio is 172.54 and the forward PE ratio is 52.45.
| PE Ratio | 172.54 |
| Forward PE | 52.45 |
| PS Ratio | 5.97 |
| PB Ratio | 3.95 |
| P/TBV Ratio | 4.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 50.27 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 182.15 |
| EV / Sales | 6.30 |
| EV / EBITDA | 90.20 |
| EV / EBIT | 226.54 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 5.97 |
| Debt / FCF | -1.28 |
| Interest Coverage | 1.89 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 1.59% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 6.62% |
| Revenue Per Employee | 11.58M |
| Profits Per Employee | 400,321 |
| Employee Count | 736 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.19M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +38.66% in the last 52 weeks. The beta is 0.48, so Orchid Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | +38.66% |
| 50-Day Moving Average | 1,001.26 |
| 200-Day Moving Average | 788.42 |
| Relative Strength Index (RSI) | 53.01 |
| Average Volume (20 Days) | 79,191 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Orchid Pharma had revenue of INR 8.52 billion and earned 294.64 million in profits. Earnings per share was 5.81.
| Revenue | 8.52B |
| Gross Profit | 3.06B |
| Operating Income | 249.04M |
| Pretax Income | 293.44M |
| Net Income | 294.64M |
| EBITDA | 607.09M |
| EBIT | 249.04M |
| Earnings Per Share (EPS) | 5.81 |
Balance Sheet
The company has 832.11 million in cash and 3.63 billion in debt, with a net cash position of -2.79 billion or -55.08 per share.
| Cash & Cash Equivalents | 832.11M |
| Total Debt | 3.63B |
| Net Cash | -2.79B |
| Net Cash Per Share | -55.08 |
| Equity (Book Value) | 12.88B |
| Book Value Per Share | 253.98 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 1.01 billion and capital expenditures -3.84 billion, giving a free cash flow of -2.82 billion.
| Operating Cash Flow | 1.01B |
| Capital Expenditures | -3.84B |
| Depreciation & Amortization | 358.05M |
| Net Borrowing | 1.72B |
| Free Cash Flow | -2.82B |
| FCF Per Share | -55.68 |
Margins
Gross margin is 35.85%, with operating and profit margins of 2.92% and 3.46%.
| Gross Margin | 35.85% |
| Operating Margin | 2.92% |
| Pretax Margin | 3.44% |
| Profit Margin | 3.46% |
| EBITDA Margin | 7.12% |
| EBIT Margin | 2.92% |
| FCF Margin | n/a |
Dividends & Yields
Orchid Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.08% |
| Shareholder Yield | 0.08% |
| Earnings Yield | 0.58% |
| FCF Yield | -5.55% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Orchid Pharma is 968.67, which is -2.24% lower than the current price. The consensus rating is "Buy".
| Price Target | 968.67 |
| Price Target Difference | -2.24% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |